U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.
FORM 4
ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
( ) Check box if no longer subject to Section 16.
Form 4 or Form 5 obligations may continue. See Instructions 1(b).
1. Name and Address of Reporting Person
Moyer, Albert J.
Allergan, Inc.
2525 Dupont Drive
Irvine, CA 92612
U.S.A.
2. Issuer Name and Ticker or Trading Symbol
Allergan, Inc.
AGN
3. IRS or Social Security Number of Reporting Person (Voluntary)
4. Statement for Month/Year
August, 1996
5. If Amendment, Date of Original (Month/Year)
6. Relationship of Reporting Person to Issuer (Check all applicable)
( ) Director ( ) 10% Owner (X) Officer (give title below) ( ) Other
(specify below)
Corporate Vice President and Chief Financial Officer
<TABLE>
<CAPTION>
___________________________________________________________________________________________________________________________________
Table I -- Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned |
___________________________________________________________________________________________________________________________________|
1. Title of Security |2. |3. |4.Securities Acquired (A) |5.Amount of |6.Dir |7.Nature of Indirect |
| Transaction | or Disposed of (D) | Securities |ect | Beneficial Ownership |
| | | | Beneficially |(D)or | |
| | | | | A/| | Owned at |Indir | |
| Date |Code|V| Amount | D | Price | End of Year |ect(I)| |
___________________________________________________________________________________________________________________________________|
<S> <C> <C> <C><C> <C> <C> <C> <C> <C>
Common Stock | | | | | | |2,000 |D | |
- -----------------------------------------------------------------------------------------------------------------------------------|
Common Stock |(1) |J (1|V|13 |A |(1) |28 |D | |
| |) | | | | | | | |
- -----------------------------------------------------------------------------------------------------------------------------------|
Common Stock |(2) |J (2|V|172 |A |(2) |270 |I |By 401(k) Trust |
| |) | | | | | | | |
- -----------------------------------------------------------------------------------------------------------------------------------|
___________________________________________________________________________________________________________________________________|
<CAPTION>
___________________________________________________________________________________________________________________________________
Table II -- Derivative Securitites Acquired, Disposed of, or Beneficially Owned |
___________________________________________________________________________________________________________________________________|
1.Title of Derivative |2.Con- |3. |4. |5.Number of De |6.Date Exer|7.Title and Amount |8.Price|9.Number |10.|11.Nature of|
Security |version |Transaction | rivative Secu |cisable and| of Underlying |of Deri|of Deriva |Dir|Indirect |
|or Exer | | | rities Acqui |Expiration | Securities |vative |tive |ect|Beneficial |
|cise | | | red(A) or Dis |Date(Month/| |Secu |Securities |(D)|Ownership |
|Price of| | | posed of(D) |Day/Year) | |rity |Benefi |or | |
|Deriva- | | | |Date |Expir| | |ficially |Ind| |
|tive | | | | A/|Exer-|ation| Title and Number | |Owned at |ire| |
|Secu- | | | | | D |cisa-|Date | of Shares | |End of |ct | |
|rity |Date |Code|V| Amount | |ble | | | |Year |(I)| |
___________________________________________________________________________________________________________________________________|
<S> <C> <C> <C> <C><C> <C> <C> <C> <C> <C> <C> <C> <C> <C>
| | | | | | | | | | | | | | |
___________________________________________________________________________________________________________________________________|
</TABLE>
Explanation of Responses:
(1) Shares were acquired from 3/8/96 through 6/14/96 under the Allergan, Inc.
Dividend Reinvestment and Stock Purchase Plan at prices ranging
from $36.938 to $40.313 per share. The information presented is as of
8/14/96.
(2) Shares were acquired from 1/1/96 through 8/14/96 under the Allergan, Inc.
Savings and Investment Plan at prices ranging from $31.25 to $41.75
per share, in transactions exempt from Section 16(b) by virtue of Rule
16b-3(c). The information presented is as of 8/14/96.
(3) Granted pursuant to the Allergan, Inc. 1989 Incentive Compensation Plan,
which complies with Rule 16b-3(d); the option becomes exercisable in
25% increments on 4/22/97, 4/22/98, 4/22/99 and
4/22/00.
SIGNATURE OF REPORTING PERSON
/s/ Albert J. Moyer
DATE
9/16/96
